SSF-Based Sunesis Pharmaceuticals, Inc.'s Shares Crater After Failed Phase 3 Cancer Drug Study

Sunesis Announces Results From Pivotal Phase 3 VALOR Trial of Vosaroxin and Cytarabine in Patients With First Relapsed or Refractory Acute Myeloid Leukemia SOUTH SAN FRANCISCO, Calif., Oct. 6, 2014 -- Sunesis Pharmaceuticals, Inc. today announced results from the pivotal Phase 3 VALOR trial, a randomized, double-blind, placebo-controlled trial of vosaroxin and cytarabine in patients with first relapsed or refractory acute myeloid leukemia . At more than 100 leading international sites, the trial enrolled 711 patients, who were stratified for age, geography and disease status.

http://ift.tt/1xVEVco